Skip to main content
MedVellum
MCQsExamsAtlas
DashboardPricing
MBBS / Core medicine✳Dermatology✳ICU Fellowship (CICM)✳Anaesthesia✳Emergency Medicine✳Psychiatry Fellowship✳Paediatrics Fellowship✳Physician Medicine✳MCQs✳SAQs✳Vivas✳OSCE✳Evidence-first✳MBBS / Core medicine✳Dermatology✳ICU Fellowship (CICM)✳Anaesthesia✳Emergency Medicine✳Psychiatry Fellowship✳Paediatrics Fellowship✳Physician Medicine✳MCQs✳SAQs✳Vivas✳OSCE✳Evidence-first✳

MedVellum.

The folio

Exam-exhaustive medical education across every specialty — evidence-graded topics, engraved plates, and practice in every written and oral format. Educational content only — not medical advice.

llms.txt · psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship
  • Paediatrics Fellowship
  • Physician Medicine

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Folio edition · Set in Instrument Serif & Archivo

Paeds SAQsneurology-neurodisability-and-neuromuscular

Paeds SAQs · neurology-neurodisability-and-neuromuscular

Antiseizure medicines: selection, adverse effects and monitoring — formative SAQs

Formative SAQs on antiseizure medicine selection, adverse effects and monitoring: classifying the drug by spectrum and enzyme effect, choosing the syndrome-matched first-choice medicine, recognising the adverse-effect signature of each agent, applying the valproate pregnancy prevention programme, and managing the lamotrigine rash scenario.

20 marks30 min
On this page & tools

Target exams

RACP General PaediatricsMRCPCH ClinicalRACP DWE

Target exams

RACP General PaediatricsMRCPCH ClinicalRACP DWE
Prompt
Selecting, monitoring and adjusting antiseizure medicines in children

SAQ 1 (10)

A ten-year-old boy with newly diagnosed focal epilepsy is started on levetiracetam. Two weeks later his parents report that he has become increasingly irritable and aggressive, with two episodes of hitting a classmate, which is unlike his baseline. His seizures are controlled. [5] [1]

a) Name the adverse effect, estimate its approximate frequency in children on this drug, and explain why this drug has a favourable interaction profile despite this behavioural effect. (3 marks) [5]

b) Outline three management options for this adverse effect, and state the principle that governs the choice between them. (3 marks) [5]

c) The family asks whether carbamazepine, used by an uncle with epilepsy, might be a better choice. State the spectrum classification of carbamazepine and explain why it is or is not appropriate for this child. (2 marks) [1]

d) Describe the baseline and follow-up monitoring you would arrange for a child on this drug, and explain why routine therapeutic drug monitoring is not required. (2 marks) [5]

SAQ 2 (10)

A fourteen-year-old girl with juvenile myoclonic epilepsy has morning myoclonic jerks and occasional generalised tonic-clonic seizures. Her neurologist has recommended valproate as the most effective single drug. She is sexually active and uses no contraception. [7] [5]

a) State the valproate pregnancy prevention programme, naming the conditions that must be met before valproate is prescribed in a girl of childbearing potential. (3 marks) [7]

b) Name two broad-spectrum alternatives to valproate for this patient and state the principle that governs the choice. (3 marks) [5] [7]

c) If lamotrigine is chosen, state the titration rule and explain why concurrent valproate would require an even slower titration. Name the severe cutaneous adverse effect the slow titration prevents. (2 marks) [11]

d) Describe the transition planning required as she moves to adult care, addressing the medicine review, contraception and pregnancy planning. (2 marks) [7]

References

  1. [1]Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia, 2013.PMID 23350722
  2. [5]Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol, 2012.PMID 22832500
  3. [7]Pack AM, Oskoui M, Williams Roberson S, et al. Teratogenesis, Perinatal, and Neurodevelopmental Outcomes After In Utero Exposure to Antiseizure Medication: Practice Guideline From the AAN, AES, and SMFM. Neurology, 2024.PMID 38748979
  4. [11]Guberman AH, Besag FM, Brodie MJ, et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia, 1999.PMID 10403224